GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes.
Uenishi GI, Repic M, Yam JY, Landuyt A, Saikumar-Lakshmi P, Guo T, Zarin P, Sassone-Corsi M, Chicoine A, Kellogg H, Hunt M, Drow T, Tewari R, Cook PJ, Yang SJ, Cerosaletti K, Schweinoch D, Guiastrennec B, James E, Patel C, Chen TF, Buckner JH, Rawlings DJ, Wickham TJ, Mueller KT.
Uenishi GI, et al. Among authors: patel c.
JCI Insight. 2024 Feb 8;9(6):e171844. doi: 10.1172/jci.insight.171844.
JCI Insight. 2024.
PMID: 38516892
Free PMC article.
Tregs have the potential to establish long-term immune tolerance in patients recently diagnosed with type 1 diabetes (T1D) by preserving beta cell function. ...
Tregs have the potential to establish long-term immune tolerance in patients recently diagnosed with type 1 diabetes (T1D) by preserv …